copy and paste this google map to your website or blog!
Press copy button and paste into your blog or website.
(Please switch to 'HTML' mode when posting into your blog. Examples: WordPress Example, Blogger Example)
Lilly Announces Complete Response Letter for Sintilimab in Combination . . . INDIANAPOLIS, March 24, 2022 PRNewswire -- Eli Lilly and Company (NYSE: LLY) today announced that the U S Food and Drug Administration (FDA) has issued a complete response letter (CRL) for the Biologics License Application (BLA) for the investigational medicine sintilimab injection, a PD-1 inhibitor in combination with pemetrexed and platinum chemotherapy for the first-line treatment of